EYPT logo

EyePoint Inc. (EYPT)

$0.31

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EYPT

Market cap

$34999527

EPS

-3.97

P/E ratio

--

Price to sales

105.1

Dividend yield

--

Beta

1.845693

Price on EYPT

Previous close

$0.31

Today's open

$0.30

Day's range

$0.28 - $0.31

52 week range

$0.28 - $19.11

Profile about EYPT

CEO

Jay Duker

Employees

214

Headquarters

Watertown, MA

Exchange

NASDAQ Global Market

Shares outstanding

113782597

Issue type

Common Stock

EYPT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on EYPT

Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)---- $EYPT #EYPT--EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.

news source

Business Wire • 2 hours ago

news preview

EyePoint, Inc. (EYPT) Presents at UBS Global Biopharma Conference 2026 Transcript

EyePoint, Inc. ( EYPT ) UBS Global Biopharma Conference 2026 November 17, 2026 3:40 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Conference Call Participants Alice Nettleton Presentation Alice Nettleton Good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference.

news source

Seeking Alpha • a day ago

news preview

EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript

EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

– Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis – – Strategic prioritization expected to generate $30 million in annualized savings – – $118 million in cash, cash equivalents and short-term investments, as of September 30, 2026 – WATERTOWN, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate developments.

news source

GlobeNewsWire • Nov 12, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates

EyePoint (EYPT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.85 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings

WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:

news source

GlobeNewsWire • Nov 6, 2026

news preview

EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m.

news source

GlobeNewsWire • Nov 5, 2026

news preview

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money

news source

GlobeNewsWire • Oct 26, 2026

news preview

¹ Disclosures

Get started with M1

Invest in EyePoint Inc.

Open an M1 investment account to buy and sell EyePoint Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EYPT on M1